Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Guggenheim reiterated their sell rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. A number of other analysts have also recently ...

Guggenheim reaffirmed their buy rating on shares of Veracyte (NASDAQ:VCYT – Free Report) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $45.00 price objective on ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

"Our alliance with Luminis Partners is an important component of our broader international focus to provide clients with strategic opportunities,” said Mark Van Lith, CEO of Guggenheim Securities. "We ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...